Vericel (VCEL) Shares Down 4.6%
Vericel Corp (NASDAQ:VCEL)’s share price fell 4.6% on Tuesday . The stock traded as low as $12.21 and last traded at $12.78. 18,632 shares traded hands during trading, a decline of 98% from the average session volume of 1,052,944 shares. The stock had previously closed at $12.22.
Several research firms have weighed in on VCEL. Needham & Company LLC cut their target price on Vericel from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Wednesday, August 8th. BidaskClub lowered Vericel from a “buy” rating to a “hold” rating in a research note on Tuesday, June 26th. BTIG Research reiterated a “buy” rating and issued a $17.00 price objective on shares of Vericel in a research note on Tuesday, August 7th. Finally, LADENBURG THALM/SH SH upgraded Vericel from a “neutral” rating to a “buy” rating in a research note on Monday, July 16th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Vericel currently has a consensus rating of “Buy” and an average price target of $15.00.
The company has a debt-to-equity ratio of 0.16, a current ratio of 7.72 and a quick ratio of 7.48. The company has a market capitalization of $604.58 million, a P/E ratio of -25.28 and a beta of 3.00.
In other news, insider Dominick Colangelo sold 75,000 shares of Vericel stock in a transaction dated Thursday, October 4th. The stock was sold at an average price of $15.02, for a total value of $1,126,500.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Gerard J. Michel sold 15,000 shares of Vericel stock in a transaction dated Monday, October 15th. The stock was sold at an average price of $12.65, for a total value of $189,750.00. Following the completion of the transaction, the chief financial officer now owns 165,960 shares in the company, valued at $2,099,394. The disclosure for this sale can be found here. Insiders sold 114,000 shares of company stock worth $1,609,770 over the last quarter. 4.70% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently modified their holdings of VCEL. Capital Fund Management S.A. bought a new position in Vericel during the second quarter valued at about $104,000. Quantitative Systematic Strategies LLC bought a new position in Vericel during the second quarter valued at about $108,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in Vericel during the second quarter valued at about $116,000. Commonwealth Equity Services LLC bought a new position in Vericel during the second quarter valued at about $123,000. Finally, Metropolitan Life Insurance Co. NY bought a new position in Vericel during the second quarter valued at about $128,000. Hedge funds and other institutional investors own 76.48% of the company’s stock.
About Vericel (NASDAQ:VCEL)
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure.
Read More: Do Tariffs Work?
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.